Development of potent bifunctional endomorphin-2 analogues with mixed μ-/δ-opioid agonist and δ-opioid antagonist properties

Journal of Medicinal Chemistry

Volumn 47, Issue 14, 2004, Pages 3591-3599

  Fujita, Yoshio ^a   Tsuda, Yuko ^a   Li, Tingyou ^a   Motoyama, Takashi ^a   Takahashi, Motohiro ^a   Shimizu, Yoshiro ^a   Yokoi, Toshio ^a   Sasaki, Yusuke ^b   Ambo, Akihiro ^b   Kita, Atsuko ^c   Jinsmaa, Yunden ^d   Bryant, Sharon D ^d   Lazarus, Lawrence H ^d   Okada, Yoshio ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',6' DIMETHYLTYROSINE; ADAMANTANE DERIVATIVE; ALIPHATIC COMPOUND; AMIDE; AROMATIC COMPOUND; BENZYL DERIVATIVE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; ENDOMORPHIN 2; ENDOMORPHIN 2 DERIVATIVE; ISOQUINOLINE DERIVATIVE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALTREXONE; NAPHTHYL GROUP; OPIATE; PHENYL GROUP; PHENYLALANINE; PROLINE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; TYROSINE; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHEMICAL BOND; CIS TRANS ISOMERISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HYDROPHOBICITY; IC 50; MALE; MOUSE; NONHUMAN;

ANALGESICS; ANIMALS; GUINEA PIGS; ILEUM; MALE; MICE; MODELS, MOLECULAR; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NEUROMUSCULAR JUNCTION; OLIGOPEPTIDES; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STEREOISOMERISM; VAS DEFERENS;

EID: 3042599035     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030649p     Document Type: Article

References (56)

1. 2O, diethyl ether; GPI, guinea pig ileum; HX, hexane; IBCF, isobutyl chloroformate; Isq, isoquinoline; MeOH, methanol; MVD, mouse vas deference; NMM, N-methylmorpholine; NMR, nuclear magnetic resonance; NOE, nuclear Overhauser effect; NOESY, nuclear Overhauser and exchange spectroscopy; Nph, naphthalene; Ph, phenyl; PyBop, benzotriazol-1- yloxytris(pyrrolidino)phosphonium hexafluorophosphate; Pyr, pyridine; Qln, quinoline; TFA, trifluoroacetic acid; THF, tetrahydrofuran; Z, benzyloxycarbonyl.
2. 2O, diethyl ether; GPI, guinea pig ileum; HX, hexane; IBCF, isobutyl chloroformate; Isq, isoquinoline; MeOH, methanol; MVD, mouse vas deference; NMM, N-methylmorpholine; NMR, nuclear magnetic resonance; NOE, nuclear Overhauser effect; NOESY, nuclear Overhauser and exchange spectroscopy; Nph, naphthalene; Ph, phenyl; PyBop, benzotriazol-1- yloxytris(pyrrolidino)phosphonium hexafluorophosphate; Pyr, pyridine; Qln, quinoline; TFA, trifluoroacetic acid; THF, tetrahydrofuran; Z, benzyloxycarbonyl.
3. 2O, diethyl ether; GPI, guinea pig ileum; HX, hexane; IBCF, isobutyl chloroformate; Isq, isoquinoline; MeOH, methanol; MVD, mouse vas deference; NMM, N-methylmorpholine; NMR, nuclear magnetic resonance; NOE, nuclear Overhauser effect; NOESY, nuclear Overhauser and exchange spectroscopy; Nph, naphthalene; Ph, phenyl; PyBop, benzotriazol-1- yloxytris(pyrrolidino)phosphonium hexafluorophosphate; Pyr, pyridine; Qln, quinoline; TFA, trifluoroacetic acid; THF, tetrahydrofuran; Z, benzyloxycarbonyl.
4. Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E. The effect of morphine- and morphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976, 197, 517-532.
5. Lord, J. A. H.; Waterfield, A. A.; Hughes, J.; Kosterlitz, H. W. Endogenous opioid peptides: multiple agonists and receptors. Nature 1977, 267, 495-499.
6. (a) DeLander, G. E.; Portoghese, P. S.; Takemori, A. E. Role of spinal mu opioid receptors in the development of morphine tolerance and dependence. J. Pharmacol. Exp. Ther. 1984, 231, 91-96.
7. (b) Abdelhamid, E. E.; Sultana, M.; Portoghese, P. S.; Takemori, A. E. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther. 1991, 258, 299-303.
8. Zadina, J. E.; Hackler, L.; Ge, L. J.; Kastin, A. J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997, 386, 499-502.
9. Hackler, L.; Zadina, J. E.; Ge, L. J.; Kastin, A. J. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides 1997, 18, 1635-1639.
10. 2): A potent and specific agonist for morphiceptin (μ) receptors. Science 1981, 212, 75-77.
11. Brantl, V.; Gramsch, C.; Lottspeich, F.; Mertz, R.; Jaeger, K. H.; Herz, A. Novel opioid peptides derived from hemoglobin: hemorphins. Eur. J. Pharmacol. 1986, 125, 309-310.
12. Horvath, A.; Kastin, A. J.; Isolation of tyrosine-melanocyte-stimulating hormone releasing factor 1 from bovine tissue. J. Biol. Chem. 1989, 264, 2175-2179.
13. 2) in human brain cortex. Int. J. Pept. Protein Res. 1990, 36, 281-284.
14. 2 (Tyr-W-MIF-1). Peptides 1992, 13, 623-631.
15. Hackler, L.; Kastin, A. J.; Echergyi, J.; Zadina, J. E. Isolation of Tyr-W-MIF-1 from bovine hypothalami. Neuropeptides 1993, 24, 159-164.
16. Hughes, J.; Smith, T. W.; Kosterlitz, H. W.; Forthergill, L. A.; Morgan, B. A.; Morris, H. R. Identification of two related pentapeptides from the brain with potent opiateagonist activity. Nature 1975, 258, 577-580.
17. Ling, N.; Burgus, R.; Guillemin, R. Isolation, primary structure and synthesis of α-endorphin and γ-endorphin, two peptides of hypothalamic-hypophysial origin with morphinomimetic activity. Proc. Natl. Acad. Sci. U.S.A. 1976, 73, 3042-3046.
18. Cox, B. M.; Goldstein, A.; Li, C. H. Opioid activity of a peptide, β-lipotorphin-(61-91), derived from β-lipotorphin. Proc. Natl. Acad. Sci. U.S.A. 1976, 73, 1821-1823.
19. Goldstein, A. G.; Fischil, W.; Lowney, L. I.; Hunkapilier, M.; Hood, L. Porcine pituitary dynorphin: complete amino acid sequence of biological active heptapeptide. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 7219-7223.
20. Handa, B. K.; Land, A. C.; Lord, J. A.; Morgen, B. A.; Rance, M. J.; Smith, C. F. Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors. Eur. J. Pharmacol. 1981, 70, 531-540.
21. Schulz, R.; Wuster, M.; Krenss, H.; Herz, A. Selective development of tolerance without dependence in multiple opiate receptors of mouse vas deferens. Nature 1980, 285, 242-243.
22. Melchiori, P.; Negri, L. The dermorphin peptide family. Gen. Pharmacol. 1996, 27, 1099-1107.
23. Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Salvadori, S. What peptides these deltorphin be. Prog. Neurobiol. 1999, 57, 377-420.
24. Podlogar, B. L.; Paterline, M. G.; Ferguson, D. M.; Leo, G. C.; Demeter, D. A.; Brown, F. K.; Reitz, A. B. Conformational analysis of the endogenous μ-opioid agonist endomorphin-1 using NMR spectroscopy and molecular modeling. FEBS Lett. 1998, 439, 13-20.
25. 1H NMR spectroscopy and molecular modeling calculation. J. Peptide Res. 2001, 58, 399-412.
26. Keller, M.; Boissard, C.; Patiny, L.; Chung, N. N.; Lemieux, C.; Mutter, M.; Schiller, P. W. Pseudoproline-containing analogues of morphiceptin and endomorphin-2: evidence for a cis Tyr-Pro amide bond in the bioactive conformation. J. Med. Chem. 2001, 44, 3896-3903.
27. 4]morphiceptin analogs incorporating cis-2-aminocyclopentane carboxylic acid as a peptidomimetics for proline. Int. J. Peptide Res. 1991, 37, 364-381.
28. Dygos, J. H.; Yonan, E. E.; Scaros, M. G.; Goodmonson, O. J.; Getman, D. P.; Periana, R. A.; Beck, G. R. A convenient asymmetric synthesis of the unnatural amino acid 2,6-dimethyl-L-tyrosine. Synthesis 1992, 8, 741-743.
29. Salvadori, S.; Attila, M.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Crescenzi, O.; Guessiini, R.; Picone, D.; Tancredi, T.; Temussi, P. A.; Lazarus, L. H. δ Opioidmimetic antagonist: prototypes for designing a new generation of ultraselective opioid peptides. Mol. Med. 1995, 1, 678-679.
30. Bryant, S. D.; Salvadori, S.; Cooper, P. S.; Lazarus, L. H. New δ-opioid antagonists as pharmacological probes. Trends. Pharmacol. Sci. 1998, 19, 42-46.
31. Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Guerrini, R.; Balboni, G.; Salvadori, S. Design of δ-opioid peptide antagonists for emerging drug applications. Drug Discovery Today 1998, 3, 284-294.
32. Sasaki, Y.; Suto, T.; Ambo, A.; Ouchi, H.; Yamamoto, Y. Biological properties of opioid peptides replacing Tyr at position 1 by 2,6-dimethyl-Tyr. Chem. Pharm. Bull. 1999, 47, 1506-1509.
33. 1]-endomorphin-2 analogues: enhanced activity and cis orientation of Dmt-Pro amide bond. Bioorg. Med. Chem. 2003, 11, 1983-1994.
34. Balboni, G.; Salvadori, S.; Guerrini, R.; Bianchi, C.; Santagada, V.; Calliendo, G.; Bryant, S. D.; Lazarus, L. H. Opioid pseudopeptides containinig heteroaromatic or heteroaliphatic nuclei. Peptides 2000, 21, 1663-1671.
35. Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant, S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic pharmacophore: Conversion of a potent δ-opioid receptor antagonist into a potent δ-agonist and ligands with mixed properties. J. Med. Chem. 2002, 45, 713-720.
36. Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H. Potent δ-opioid receptor agonists containig the Dmt-Tic Pharmacophore. J. Med. Chem. 2002, 45, 5556-5563.
37. Ishii, S.; Witkop, B.; Gramicidin, A. I. Determination of composition and amino acid configuration by enzymatic and gas chromatographic methods. J. Am. Chem. Soc. 1963, 85, 1832-1834.
38. Goldschmidt, S.; Lautenschlager, H. Zur Darstellung Optischaktiver Dipeptide nach der Phosphorazomethode (The synthesis of optically active dipeptide by the phosphazo method). Chem. Ber. 1958, 91, 449-455.
39. Vughan, J. R.; Osato, R. L. The preparation of peptides using mixed carbonic-carboxylic acid anhydrides. J. Am. Chem. Soc. 1952, 74, 676-678.
40. Honzl, J.; Rudinger, J. Nitrosyl chloride and butyl nitrite as reagents in peptide synthesis by the azide method; suppression of amide formation. Collect. Czech. Chem. Commun. 1961, 26, 2333-2344.
41. Coste, J.; Le-Nguyn, D.; Castro, B. PyBOP: A new peptide coupling reagent devoid of toxic by-product. Tetrahedron Lett. 1990, 31, 205-208.
42. Temussi, P. A.; Salvadori, S.; Amodeo, P.; Bianchi, C.; Guerrini, R.; Tomatis, R.; Lazarus, L. H.; Picone, D.; Tancredi, T. Selective opioid dipeptides. Biochem. Biophys. Res. Commun. 1994, 198, 933-939.
43. Capasso, A.; Guerrini, R.; Balboni, G.; Sorrentino, L.; Temussi, P. A.; Lazarus, L. H.; Bryant, S. D.; Salvadori, S. Dmt-Tic-OH, a high selective and potent δ opioidmimetic receptor antagonist after systemic administration in the mouse. Life Sci. 1996, 59, PL93-PL98.
44. Salvadori, S.; Guerrini, R.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazarus, L. H. Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow δ antagonist to manifest γ agonism or δ antagonism. J. Med. Chem. 1999, 42, 5010-5019.
45. Page, D.; Naismith, A.; Schmidt, R.; Coupal, M.; Labarre, M.; Gosselin, M.; Bellemare, D.; Payza, K.; Brown, W. Novel C-terminus modifications of the Dmt-Tic motif: a new class of dipeptide analogues showing altered pharmacological profiles toward the opioid receptors. J. Med. Chem. 2001, 44, 2387-2390.
46. Okada, Y.; Tsuda, Y.; Fujita, Y.; Yokoi, T.; Sasaki, Y.; Ambo, A.; Konishi, R.; Nagata, M.; Salvadori, S.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H. Unique high affinity synthetic γ-opioid receptor agonists with central- and systemic-mediated analgesia. J. Med. Chem. 2003, 46, 3201-3209.
47. Malfroy, B.; Swerts, J. P.; Guyon, A. Roques, B. P.; Schwartz, J. C. High-affinty enkephalin-degrading peptidase in brain is increased after morphine. Nature 1978, 276, 523-526.
48. (a) Tomboly, C.; Peter, A.; Toth, G. In vitro quantitative study of the degradation of endomorphins. Peptides 2002, 23, 1573-1580.
49. (b) Shane, R.; Wilk, S.; Bodnar, R. J. Modulation of endomorphin-2 induced analgesia by dipeptidyl peptidase IV. Brain Res. 1999, 815, 278-286.
50. Cardillo, G.; Gentilucci, L.; Qasem, A. R.; Sgarzi, F.; Spampinato, S. Endomorphin-1 analogues containing β-proline are μ-opioid receptor agonists and display enhanced enzymatic hydrolysis resistance. J. Med. Chem. 2002, 45, 2571-2578.
51. Lazarus, L. H.; Salvadori, S.; Santagaga, V.; Tomatis, R.; Wilson, W. E. Function of negative charge in the "address domain" of deltorphins. J. Med. Chem. 1991, 34, 1350-1359.
52. Lazarus, L. H.; Salvadori, S.; Attila, M.; Grieco, P.; Bundy, D. M.; Wilson, W. E.; Tomatis, R. Interaction of deltorphin with opioid receptors: Molecular determinants for affinity and selectivity. Peptides 1993, 14, 21-28.
53. Rang, H. P. Stimulant actions of volatile anaesthetics on smooth muscle. Br. J. Pharmcol. 1964, 22, 356-365.
54. Hughes, J.; Kosterlitz, H. W.; Leslie, F. M. Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antagonist potencies of narcotic analgesics. Br. J. Pharmacol. 1975, 53, 371-381.
55. Arunlakshana, O.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959, 14, 48-58.
56. Ueda, H.; Amano, H.; Shiomi, H.; Takagi, H. Comparison of the analgesic effects of various opioid peptides by a newly devised intracisternal injection technique in conscious mice. Eur. J. Pharmacol. 1979, 56, 265-268.